MCID: GND003
MIFTS: 32

Gonadal Disease

Categories: Endocrine diseases

Aliases & Classifications for Gonadal Disease

MalaCards integrated aliases for Gonadal Disease:

Name: Gonadal Disease 12 14
Gonadal Disorders 41 69
Gonadal Dysfunction 51

Classifications:



External Ids:

Disease Ontology 12 DOID:2277
MeSH 41 D006058
NCIt 46 C26786
UMLS 69 C0018050

Summaries for Gonadal Disease

Disease Ontology : 12 An endocrine system disease that is located in the gonads.

MalaCards based summary : Gonadal Disease, also known as gonadal disorders, is related to pituitary tumors and pituitary adenoma, prolactin-secreting. An important gene associated with Gonadal Disease is POMC (Proopiomelanocortin), and among its related pathways/superpathways are Peptide ligand-binding receptors and GPCRs, Other. The drugs Methyltestosterone and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include the gonads, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Related Diseases for Gonadal Disease

Diseases related to Gonadal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 111)
# Related Disease Score Top Affiliating Genes
1 pituitary tumors 30.1 GH1 IGF1 POMC
2 pituitary adenoma, prolactin-secreting 30.1 GH1 IGF1 POMC
3 acromegaly 30.0 GH1 IGF1 POMC
4 hypogonadism 29.9 ANOS1 GNRH1 GNRHR KISS1 KISS1R NR0B1
5 prader-willi syndrome 29.9 GH1 GNRH1 IGF1 POMC
6 pituitary gland disease 29.8 CRH GH1 GNRH1 IGF1 POMC
7 hypopituitarism 29.7 CRH GH1 GNRH1 IGF1 POMC
8 sex differentiation disease 28.8 AMH AR GNRH1 POMC SHBG SRY
9 acidophil adenoma 10.6 IGF1 POMC
10 lymphocytic hypophysitis 10.6 GH1 POMC
11 adenohypophysitis 10.6 GH1 POMC
12 pituitary infarct 10.5 GNRH1 IGF1 POMC
13 chiasmal syndrome 10.5 GNRH1 POMC
14 anorchia 10.5 NR5A1 SRY
15 empty sella syndrome 10.5 GH1 GNRH1 POMC
16 adrenal rest tumor 10.5 GNRH1 NR5A1 POMC
17 hyperpituitarism 10.5 GH1 IGF1 POMC
18 hypothyroidism, congenital, nongoitrous, 4 10.5 GH1 IGF1 POMC
19 pseudohypoparathyroidism, type ia 10.5 GH1 IGF1
20 chromophobe adenoma 10.5 GH1 GNRH1 POMC
21 sheehan syndrome 10.5 CRH IGF1 POMC
22 fasting hypoglycemia 10.5 CRH IGF1 POMC
23 pituitary-dependent cushing's disease 10.5 CRH GNRH1 POMC
24 persistent fetal circulation syndrome 10.5 CRH IGF1 POMC
25 endocrine organ benign neoplasm 10.5 CRH IGF1 POMC
26 47, xxy 10.5 AR SHBG
27 pituitary hormone deficiency, combined, 2 10.5 GH1 IGF1 POMC
28 pituitary adenoma 1, multiple types 10.5 GH1 IGF1
29 pituitary apoplexy 10.5 GNRH1 POMC
30 adrenal gland hyperfunction 10.5 CRH GH1 POMC
31 chronic fatigue syndrome 10.4 CRH IGF1 POMC
32 hypogonadotropic hypogonadism 23 without anosmia 10.4 GNRH1 GNRHR
33 postmenopausal atrophic vaginitis 10.4 AR SHBG
34 lipoid congenital adrenal hyperplasia 10.4 NR5A1 POMC SRY
35 withdrawal disorder 10.4 AR CRH POMC
36 overnutrition 10.4 IGF1 POMC SHBG
37 ovarian hyperstimulation syndrome 10.4 AMH FSHR GNRH1
38 acth deficiency, isolated 10.4 CRH POMC
39 acquired metabolic disease 10.4 IGF1 POMC SHBG
40 freemartinism 10.4 AMH GNRH1 SRY
41 mccune-albright syndrome 10.4 AMH GH1 IGF1
42 nodular prostate 10.4 AR GNRH1
43 hypothalamic disease 10.4 CRH GH1 GNRH1 POMC
44 adrenal cortex disease 10.4 CRH NR0B1 POMC
45 adrenal gland disease 10.4 CRH NR0B1 POMC
46 hyperprolactinemia 10.4 GH1 GNRH1 IGF1 POMC
47 varicocele 10.4 AMH GNRH1 SHBG
48 hypoadrenocorticism, familial 10.4 CRH NR0B1 POMC
49 androgen insensitivity, partial 10.4 AR SHBG
50 persistent mullerian duct syndrome 10.4 AMH NR5A1 SRY

Graphical network of the top 20 diseases related to Gonadal Disease:



Diseases related to Gonadal Disease

Symptoms & Phenotypes for Gonadal Disease

MGI Mouse Phenotypes related to Gonadal Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.25 KISS1R NR0B1 NR5A1 POMC PROKR2 FSHR
2 homeostasis/metabolism MP:0005376 10.21 PROKR2 SHOX2 KISS1R NR0B1 NR5A1 POMC
3 growth/size/body region MP:0005378 10.18 PROKR2 SHOX2 KISS1R NR5A1 POMC KISS1
4 integument MP:0010771 10.02 PROKR2 KISS1R POMC IGF1 FSHR KISS1
5 adipose tissue MP:0005375 10 KISS1R POMC KISS1 CRH IGF1 FSHR
6 nervous system MP:0003631 9.9 KISS1 PROKR2 SHOX2 KISS1R NR5A1 POMC
7 neoplasm MP:0002006 9.8 NR0B1 POMC IGF1 FSHR AMH GNRH1
8 renal/urinary system MP:0005367 9.56 KISS1R POMC CRH IGF1 KISS1 GNRH1
9 reproductive system MP:0005389 9.36 KISS1R NR0B1 NR5A1 PROKR2 FSHR KISS1

Drugs & Therapeutics for Gonadal Disease

Drugs for Gonadal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 752)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-18-4 6010
2
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0 6013
3
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 53714-56-0 657181 3911
4
Cyproterone Acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 427-51-0
5
Drospirenone Approved Phase 4,Phase 3,Phase 1,Not Applicable 67392-87-4 68873
6
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
7
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-63-6 5991
8
Orlistat Approved, Investigational Phase 4,Phase 2,Not Applicable 96829-58-2 3034010
9
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 657-24-9 4091 14219
10
Ganirelix Approved Phase 4,Phase 2,Early Phase 1,Not Applicable 124904-93-4, 123246-29-7 25081094
11
Dihydrotachysterol Approved Phase 4,Phase 2,Phase 1 67-96-9 5311071 5281010
12
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 57-83-0 5994
13
Zinc Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 7440-66-6 32051 23994
14
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 112809-51-5 3902
15
Pioglitazone Approved, Investigational Phase 4,Not Applicable,Early Phase 1 111025-46-8 4829
16
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-43-4 5816
17 Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 329-65-7
18
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
19
Simvastatin Approved Phase 4,Phase 3,Not Applicable 79902-63-9 54454
20
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
21
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
22
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-23-7 657311 5754
23
Resveratrol Approved, Experimental, Investigational Phase 4,Phase 1,Not Applicable 501-36-0 445154
24
Lenograstim Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 135968-09-1
25
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 216974-75-3
26
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
27
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
28
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 71-58-9
29
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 763113-22-0 23725625
30
Dutasteride Approved, Investigational Phase 4,Phase 2,Phase 1 164656-23-9 6918296 152945
31
Buserelin Approved, Investigational Phase 4 57982-77-1
32
Menotropins Approved Phase 4,Phase 1,Phase 2,Not Applicable 9002-68-0, 61489-71-2 5360545
33
Nafarelin Approved Phase 4 76932-56-4 25077649 16129618
34
Liraglutide Approved Phase 4 204656-20-2 44147092
35
Aspirin Approved, Vet_approved Phase 4,Phase 2,Early Phase 1 50-78-2 2244
36
Alogliptin Approved Phase 4 850649-61-5 11450633
37
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 616-91-1 12035
38
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
39
Sevoflurane Approved, Vet_approved Phase 4,Phase 2,Not Applicable 28523-86-6 5206
40
Citalopram Approved Phase 4 59729-33-8 2771
41
Danazol Approved Phase 4 17230-88-5 28417
42
Hydroxocobalamin Approved Phase 4,Not Applicable 13422-51-0 5460373 44475014 11953898
43
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
44
Acarbose Approved, Investigational Phase 4,Not Applicable 56180-94-0 441184
45
Tranexamic Acid Approved Phase 4 1197-18-8 5526
46
Norethindrone Approved Phase 4,Phase 2,Not Applicable,Early Phase 1 68-22-4 6230
47
Rosiglitazone Approved, Investigational Phase 4,Not Applicable 122320-73-4 77999
48
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
49
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741 24759
50
Anastrozole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 120511-73-1 2187

Interventional clinical trials:

(show top 50) (show all 2775)

# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism Unknown status NCT02310074 Phase 4 Pulsatile Gonadotropin Releasing Hormone;Human chorionic gonadotropin;Urinary Follicle-Stimulating Hormone
2 Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men Unknown status NCT01699178 Phase 4 Oral testosterone undecanoate;Transdermal testosterone gel (AndroGel)
3 Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls Unknown status NCT01278290 Phase 4 Triptorelin acetate and Gonadorelin acetate;Gonadorelin acetate and Triptorelin acetate
4 Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children Unknown status NCT00438217 Phase 4 Triptorelin (GnRH agonists);Leuprolide (GnRH agonists)
5 Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism Unknown status NCT02140515 Phase 4 Lutropin alfa;Follitropin alfa and Lutropin alfa
6 Effect of Androgel on Type 2 Diabetic Males With Hypogonadism Unknown status NCT00350701 Phase 4 androgel;androgel 10g;placebo
7 Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism Unknown status NCT01084369 Phase 4 Testosterone
8 Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men Unknown status NCT00700024 Phase 4 Testim;placebo
9 Endometrial Scratching During Laproscopic Ovarian Drilling in Subfertile PCOS Women Unknown status NCT02140398 Phase 4
10 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
11 The Impact on Ovarian Reserve After Single-port, Two-port, or Four-port Access Laparoscopic Ovarian Cyst Enucleation Unknown status NCT01631253 Phase 4
12 Effects of ADSC Therapy in Women With POF Unknown status NCT01853501 Phase 4
13 the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome Unknown status NCT01752270 Phase 4 Diane-35 pretreatment;Diane-35 pretreatment
14 The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
15 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
16 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
17 Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation Unknown status NCT01103518 Phase 4 Ethinyl Estradiol + Cyproterone acetate
18 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4 Metformin
19 Testosterone for Peripheral Vascular Disease Unknown status NCT00504712 Phase 4 Testosterone;0.9% saline
20 Metformin in Infertile PCOS Patients Unknown status NCT00501904 Phase 4 Metformin
21 Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
22 Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
23 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4 Metformin and FSHr
24 Efficacy of Fenugreek Seed and Lespedeza Cuneata in TDS Completed NCT03057899 Phase 4 TFG capsules (200 mg /capsule);Placebo oral capsule
25 Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™ Completed NCT02937740 Phase 4 NATESTO Testosterone Nasal Gel
26 Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty Completed NCT02920515 Phase 4 Triptorlin or Leuprorelin;Zhibo dihuang pills;Dabu ying pills
27 The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism Completed NCT02111473 Phase 4 Testosterone
28 The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel Completed NCT01893281 Phase 4 Topical Testosterone Solution
29 Vitamin D Treatment and Hypogonadism in Men Completed NCT01748370 Phase 4 Vitamin D supplementation in hypogonadal men;Vitamin D supplementation in eugonadal men;Placebo hypogonadal;Placebo eugonadal
30 The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty Completed NCT01634321 Phase 4 Luphere depot 3.75mg(Leuprolide acetate 3.75mg)
31 Effects of Medications in Patients With Hypogonadism Completed NCT01601327 Phase 4 Testosterone enanthate (Sustanon 250 mg);Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU);Testosteron gel (Testojel 50 mg)
32 The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups Completed NCT01454011 Phase 4 Testosteron 250mg injection;Testosterone 50mg transdermal application
33 Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism Completed NCT01107067 Phase 4 Sustanon
34 Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement Completed NCT00752869 Phase 4 dutasteride;placebo
35 Effects of Testosterone on Myocardial Repolarization Completed NCT03126656 Phase 4 Testosterone Undecanoate
36 Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM) Completed NCT01560546 Phase 4 Testosterone;Placebo
37 Testosterone for Men With Insulin Treated Type 2 Diabetes Completed NCT00349362 Phase 4 Testosterone;0.9% saline
38 Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS Completed NCT01815138 Phase 4 hCG;hCG
39 Endometrial Receptivity After GnRH Agonist Triggering Completed NCT01500863 Phase 4 hCG;triptorelin;Triptorelin, estradiol valerate, micronized vaginal progesterone;triptorelin, hCG;triptorelin, hCG;triptorelin, recombinant LH
40 Testosterone Replacement in Men With Diabetes and Obesity Completed NCT01127659 Phase 4 testosterone;placebo
41 Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles Completed NCT00627406 Phase 4 Buserelin and Pregnyl;Pregnyl;Buserelin and Pregnyl;Pregnyl
42 The Use of GnRH Agonist Trigger in the Prevention of OHSS Completed NCT00349258 Phase 4 Leuprolide acetate
43 TRADE-Testosterone Replacement and Dutasteride Effectiveness Completed NCT00194675 Phase 4 Dutasteride;Testosterone gel;Placebo dutasteride
44 Endothelial Dysfunction, Inflammation and Insulin Resistance in Congenital Hypogonadism and Effect of Testosteron Replacement Therapy Completed NCT02171390 Phase 4 Testosterone 250mg injection;Testosteron 50 mg transdermal gel
45 FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST) Completed NCT01969201 Phase 4 Urofollitrophin;Follitrophin alpha
46 The Effect of Testosterone Replacement on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Hypogonadotrophic Hypogonadism Completed NCT01533129 Phase 4 Testogel 50 mg transdermal gel;Testosterone 250mg injection
47 Gonadotrophin Dosage Using a Threshold Nomogram for Ovulation Induction in WHO Group II Anovulatory Infertility Completed NCT01250821 Phase 4 Menopur
48 Metabolic Syndrome Criteria and the Effect of Testosterone Treatment in Young Men With Hypogonadism Completed NCT01160341 Phase 4 Testosteron
49 Short Versus Long Protocol for IVF and IVF+ICSI Completed NCT00756028 Phase 4 Patients receiving short protocol IVF/ICSI-treatment.;Long protocol
50 The Therapy of Nebido as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction Completed NCT00421460 Phase 4 Testosterone Undecanoate,1000mg

Search NIH Clinical Center for Gonadal Disease

Cochrane evidence based reviews: gonadal disorders

Genetic Tests for Gonadal Disease

Anatomical Context for Gonadal Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Gonadal Disease:

18
The Gonads

Publications for Gonadal Disease

Articles related to Gonadal Disease:

# Title Authors Year
1
CBX2 gene analysis in patients with 46,XY and 46,XX gonadal disorders of sex development. ( 23219007 )
2013
2
Partial deletion of the NR5A1 (SF1) gene detected by synthetic probe MLPA in a patient with XY gonadal disorder of sex development. ( 21654157 )
2011

Variations for Gonadal Disease

Expression for Gonadal Disease

Search GEO for disease gene expression data for Gonadal Disease.

GO Terms for Gonadal Disease

Cellular components related to Gonadal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 AMH ANOS1 CRH GH1 GNRH1 IGF1
2 extracellular space GO:0005615 9.23 AMH ANOS1 CRH GH1 GNRH1 IGF1

Biological processes related to Gonadal Disease according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.96 AMH GH1 GNRH1 IGF1 POMC
2 positive regulation of gene expression GO:0010628 9.89 AMH AR CRH IGF1 NR5A1
3 cell-cell signaling GO:0007267 9.85 AMH AR GNRH1 NR5A1 POMC
4 neuropeptide signaling pathway GO:0007218 9.78 KISS1R POMC PROKR2
5 positive regulation of MAPK cascade GO:0043410 9.77 AR IGF1 KISS1
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.72 FSHR GH1 IGF1
7 male gonad development GO:0008584 9.71 AR FSHR NR0B1 NR5A1
8 steroid hormone mediated signaling pathway GO:0043401 9.7 AR NR0B1 NR5A1
9 intracellular receptor signaling pathway GO:0030522 9.65 AR NR0B1 NR5A1
10 hypothalamus development GO:0021854 9.59 CRH NR0B1
11 Leydig cell differentiation GO:0033327 9.58 AR NR0B1
12 regulation of systemic arterial blood pressure GO:0003073 9.58 AR FSHR
13 positive regulation of intracellular estrogen receptor signaling pathway GO:0033148 9.57 AR FSHR
14 positive regulation of male gonad development GO:2000020 9.54 NR5A1 SRY
15 sex differentiation GO:0007548 9.54 AMH AR SRY
16 adrenal gland development GO:0030325 9.5 CRH NR0B1 NR5A1
17 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.43 AR GH1 IGF1
18 gonad development GO:0008406 9.33 AMH FSHR NR0B1
19 male sex determination GO:0030238 9.13 GNRH1 NR0B1 SRY
20 sex determination GO:0007530 8.8 AMH NR0B1 NR5A1
21 signal transduction GO:0007165 10.16 AR CRH FSHR GNRH1 GNRHR IGF1
22 G-protein coupled receptor signaling pathway GO:0007186 10.03 CRH FSHR GNRH1 GNRHR KISS1 KISS1R

Molecular functions related to Gonadal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.77 AR NR0B1 NR5A1 SHOX SHOX2
2 steroid hormone receptor activity GO:0003707 9.43 AR NR0B1 NR5A1
3 G-protein coupled peptide receptor activity GO:0008528 9.4 FSHR KISS1R
4 nuclear receptor activity GO:0004879 9.33 AR NR0B1 NR5A1
5 protein-hormone receptor activity GO:0016500 9.32 FSHR GNRHR
6 hormone activity GO:0005179 9.1 AMH CRH GH1 GNRH1 IGF1 POMC
7 androgen binding GO:0005497 8.96 AR SHBG

Sources for Gonadal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....